VERTEX PHARMACEUTICALS INC (VX1.DE) Stock Fundamental Analysis
FRA:VX1 • US92532F1003
417.5 EUR
+13.15 (+3.25%)
Last: Feb 27, 2026, 07:00 PM
VX1 gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 75 industry peers in the Biotechnology industry. VX1 scores excellent points on both the profitability and health parts. This is a solid base for a good stock. VX1 has a decent growth rate and is not valued too expensively. With these ratings, VX1 could be worth investigating further for quality investing!.
1. Profitability
1.1 Basic Checks
- VX1 had positive earnings in the past year.
- In the past year VX1 had a positive cash flow from operations.
- Of the past 5 years VX1 4 years were profitable.
- The reported operating cash flow has been mixed in the past 5 years: VX1 reported negative operating cash flow in multiple years.
1.2 Ratios
- VX1 has a Return On Assets of 14.78%. This is amongst the best in the industry. VX1 outperforms 89.61% of its industry peers.
- The Return On Equity of VX1 (21.22%) is better than 92.21% of its industry peers.
- Looking at the Return On Invested Capital, with a value of 15.66%, VX1 belongs to the top of the industry, outperforming 93.51% of the companies in the same industry.
- Measured over the past 3 years, the Average Return On Invested Capital for VX1 is above the industry average of 12.19%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.78% | ||
| ROE | 21.22% | ||
| ROIC | 15.67% |
ROA(3y)9.65%
ROA(5y)12.94%
ROE(3y)12.83%
ROE(5y)17.11%
ROIC(3y)15.82%
ROIC(5y)17.01%
1.3 Margins
- VX1 has a better Profit Margin (31.35%) than 88.31% of its industry peers.
- In the last couple of years the Profit Margin of VX1 has declined.
- VX1's Operating Margin of 38.70% is amongst the best of the industry. VX1 outperforms 92.21% of its industry peers.
- In the last couple of years the Operating Margin of VX1 has declined.
- VX1 has a better Gross Margin (86.28%) than 76.62% of its industry peers.
- VX1's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 38.7% | ||
| PM (TTM) | 31.35% | ||
| GM | 86.28% |
OM growth 3Y-7.71%
OM growth 5Y-3.24%
PM growth 3Y-3.97%
PM growth 5Y-5.49%
GM growth 3Y-0.63%
GM growth 5Y-0.43%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so VX1 is creating value.
- Compared to 1 year ago, VX1 has less shares outstanding
- The number of shares outstanding for VX1 has been reduced compared to 5 years ago.
- VX1 has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- VX1 has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | N/A |
ROIC/WACC1.82
WACC8.61%
2.3 Liquidity
- VX1 has a Current Ratio of 2.36. This indicates that VX1 is financially healthy and has no problem in meeting its short term obligations.
- VX1 has a Current ratio of 2.36. This is comparable to the rest of the industry: VX1 outperforms 50.65% of its industry peers.
- A Quick Ratio of 2.00 indicates that VX1 should not have too much problems paying its short term obligations.
- VX1's Quick ratio of 2.00 is in line compared to the rest of the industry. VX1 outperforms 46.75% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.36 | ||
| Quick Ratio | 2 |
3. Growth
3.1 Past
- VX1 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 6248.28%, which is quite impressive.
- The Earnings Per Share has been growing by 12.27% on average over the past years. This is quite good.
- Looking at the last year, VX1 shows a quite strong growth in Revenue. The Revenue has grown by 8.90% in the last year.
- Measured over the past years, VX1 shows a quite strong growth in Revenue. The Revenue has been growing by 14.10% on average per year.
EPS 1Y (TTM)6248.28%
EPS 3Y7.33%
EPS 5Y12.27%
EPS Q2Q%26.38%
Revenue 1Y (TTM)8.9%
Revenue growth 3Y10.35%
Revenue growth 5Y14.1%
Sales Q2Q%9.55%
3.2 Future
- VX1 is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.80% yearly.
- VX1 is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.17% yearly.
EPS Next Y10.74%
EPS Next 2Y11.49%
EPS Next 3Y10.83%
EPS Next 5Y11.8%
Revenue Next Year9.09%
Revenue Next 2Y9.66%
Revenue Next 3Y10.22%
Revenue Next 5Y9.17%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 26.76, VX1 can be considered very expensive at the moment.
- 80.52% of the companies in the same industry are more expensive than VX1, based on the Price/Earnings ratio.
- VX1 is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 27.07, which is the current average of the S&P500 Index.
- VX1 is valuated rather expensively with a Price/Forward Earnings ratio of 24.17.
- VX1's Price/Forward Earnings ratio is rather cheap when compared to the industry. VX1 is cheaper than 83.12% of the companies in the same industry.
- VX1's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 28.05.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 26.76 | ||
| Fwd PE | 24.17 |
4.2 Price Multiples
- 80.52% of the companies in the same industry are more expensive than VX1, based on the Enterprise Value to EBITDA ratio.
- Based on the Price/Free Cash Flow ratio, VX1 is valued cheaper than 84.42% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 37.47 | ||
| EV/EBITDA | 25.07 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates VX1 does not grow enough to justify the current Price/Earnings ratio.
- The decent profitability rating of VX1 may justify a higher PE ratio.
PEG (NY)2.49
PEG (5Y)2.18
EPS Next 2Y11.49%
EPS Next 3Y10.83%
5. Dividend
5.1 Amount
- No dividends for VX1!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
FRA:VX1 (2/27/2026, 7:00:00 PM)
417.5
+13.15 (+3.25%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-12 2026-02-12/amc
Earnings (Next)05-04 2026-05-04
Inst Owners97.56%
Inst Owner ChangeN/A
Ins Owners0.13%
Ins Owner ChangeN/A
Market Cap105.93B
Revenue(TTM)12.00B
Net Income(TTM)3.68B
Analysts80
Price Target461.23 (10.47%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.29%
Min EPS beat(2)3.12%
Max EPS beat(2)3.45%
EPS beat(4)2
Avg EPS beat(4)-0.92%
Min EPS beat(4)-7.2%
Max EPS beat(4)3.45%
EPS beat(8)5
Avg EPS beat(8)-64.05%
EPS beat(12)7
Avg EPS beat(12)-42.39%
EPS beat(16)10
Avg EPS beat(16)-31.28%
Revenue beat(2)1
Avg Revenue beat(2)-0.58%
Min Revenue beat(2)-1.21%
Max Revenue beat(2)0.06%
Revenue beat(4)2
Avg Revenue beat(4)-0.82%
Min Revenue beat(4)-4.8%
Max Revenue beat(4)2.68%
Revenue beat(8)3
Avg Revenue beat(8)-0.69%
Revenue beat(12)4
Avg Revenue beat(12)-0.78%
Revenue beat(16)7
Avg Revenue beat(16)-0.32%
PT rev (1m)6.21%
PT rev (3m)7.06%
EPS NQ rev (1m)-0.41%
EPS NQ rev (3m)-0.58%
EPS NY rev (1m)0.15%
EPS NY rev (3m)-1.34%
Revenue NQ rev (1m)-0.22%
Revenue NQ rev (3m)-0.15%
Revenue NY rev (1m)0.47%
Revenue NY rev (3m)-0.46%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 26.76 | ||
| Fwd PE | 24.17 | ||
| P/S | 10.67 | ||
| P/FCF | 37.47 | ||
| P/OCF | 33.63 | ||
| P/B | 7.22 | ||
| P/tB | 7.91 | ||
| EV/EBITDA | 25.07 |
EPS(TTM)15.6
EY3.74%
EPS(NY)17.27
Fwd EY4.14%
FCF(TTM)11.14
FCFY2.67%
OCF(TTM)12.41
OCFY2.97%
SpS39.14
BVpS57.82
TBVpS52.76
PEG (NY)2.49
PEG (5Y)2.18
Graham Number142.46
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.78% | ||
| ROE | 21.22% | ||
| ROCE | 22.25% | ||
| ROIC | 15.67% | ||
| ROICexc | 22.65% | ||
| ROICexgc | 25.38% | ||
| OM | 38.7% | ||
| PM (TTM) | 31.35% | ||
| GM | 86.28% | ||
| FCFM | 28.47% |
ROA(3y)9.65%
ROA(5y)12.94%
ROE(3y)12.83%
ROE(5y)17.11%
ROIC(3y)15.82%
ROIC(5y)17.01%
ROICexc(3y)28.12%
ROICexc(5y)40.76%
ROICexgc(3y)34.64%
ROICexgc(5y)58.61%
ROCE(3y)22.47%
ROCE(5y)24.17%
ROICexgc growth 3Y-38.98%
ROICexgc growth 5Y-26.28%
ROICexc growth 3Y-31.44%
ROICexc growth 5Y-19.05%
OM growth 3Y-7.71%
OM growth 5Y-3.24%
PM growth 3Y-3.97%
PM growth 5Y-5.49%
GM growth 3Y-0.63%
GM growth 5Y-0.43%
F-Score7
Asset Turnover0.47
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 189.83% | ||
| Cap/Sales | 3.25% | ||
| Interest Coverage | 374.91 | ||
| Cash Conversion | 78.49% | ||
| Profit Quality | 90.81% | ||
| Current Ratio | 2.36 | ||
| Quick Ratio | 2 | ||
| Altman-Z | N/A |
F-Score7
WACC8.61%
ROIC/WACC1.82
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)6248.28%
EPS 3Y7.33%
EPS 5Y12.27%
EPS Q2Q%26.38%
EPS Next Y10.74%
EPS Next 2Y11.49%
EPS Next 3Y10.83%
EPS Next 5Y11.8%
Revenue 1Y (TTM)8.9%
Revenue growth 3Y10.35%
Revenue growth 5Y14.1%
Sales Q2Q%9.55%
Revenue Next Year9.09%
Revenue Next 2Y9.66%
Revenue Next 3Y10.22%
Revenue Next 5Y9.17%
EBIT growth 1Y5.79%
EBIT growth 3Y1.84%
EBIT growth 5Y10.4%
EBIT Next Year6.57%
EBIT Next 3Y12.66%
EBIT Next 5Y11.86%
FCF growth 1Y346.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y541.25%
OCF growth 3YN/A
OCF growth 5YN/A
VERTEX PHARMACEUTICALS INC / VX1.DE FAQ
What is the ChartMill fundamental rating of VERTEX PHARMACEUTICALS INC (VX1.DE) stock?
ChartMill assigns a fundamental rating of 6 / 10 to VX1.DE.
What is the valuation status for VX1 stock?
ChartMill assigns a valuation rating of 5 / 10 to VERTEX PHARMACEUTICALS INC (VX1.DE). This can be considered as Fairly Valued.
What is the profitability of VX1 stock?
VERTEX PHARMACEUTICALS INC (VX1.DE) has a profitability rating of 7 / 10.
How financially healthy is VERTEX PHARMACEUTICALS INC?
The financial health rating of VERTEX PHARMACEUTICALS INC (VX1.DE) is 7 / 10.
What is the earnings growth outlook for VERTEX PHARMACEUTICALS INC?
The Earnings per Share (EPS) of VERTEX PHARMACEUTICALS INC (VX1.DE) is expected to grow by 10.74% in the next year.